Filing Details
- Accession Number:
- 0001209191-23-031243
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-05-19 18:48:18
- Reporting Period:
- 2023-05-17
- Accepted Time:
- 2023-05-19 18:48:18
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1070494 | Acadia Pharmaceuticals Inc | ACAD | Pharmaceutical Preparations (2834) | 061376651 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1899977 | C. Mark Schneyer | C/O Acadia Pharmaceuticals Inc. 12830 El Camino Real, Suite 400 San Diego CA 92130 | Evp, Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-05-17 | 14,869 | $0.00 | 22,346 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2023-05-17 | 14,869 | $0.00 | 37,215 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-05-17 | 15,310 | $22.50 | 21,905 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2023-05-17 | 14,869 | $0.00 | 14,869 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2023-05-17 | 14,869 | $0.00 | 14,869 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 24,782 | No | 4 | M | Direct | ||
| 24,782 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
- The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
- The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.
- The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.
Billionaire Hedge Funds
